BiotechTube

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Percutaneous Coronary Intervention

Conditions

Percutaneous Coronary Intervention, Peripheral Endovascular Intervention

Trial Timeline

Jul 23, 2025 → Dec 1, 2029

NCT ID
NCT06909565

About Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo) is a approved stage product being developed by Novartis for Percutaneous Coronary Intervention. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06909565. Target conditions include Percutaneous Coronary Intervention, Peripheral Endovascular Intervention.

What happened to similar drugs?

1 of 1 similar drugs in Percutaneous Coronary Intervention were approved

Approved (1) Terminated (0) Active (0)
✅Clopidogrel + TicagrelorAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06909565ApprovedRecruiting

Competing Products

3 competing products in Percutaneous Coronary Intervention

See all competitors
ProductCompanyStageHype Score
Clopidogrel + TicagrelorAstraZenecaApproved
43
Enoxaparin sodiumSanofiPhase 2/3
38
Otamixaban (XRP0673) + Unfractionated HeparinSanofiPhase 2
35